(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 September 2020 (17.09.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/181376 A1

(51) International Patent Classification:
C07K 16/18 (2006.01) *C12N 15/13* (2006.01)
A61K 39/395 (2006.01) *C12P 21/08* (2006.01)

(21) International Application Number:
PCT/CA2020/050321

(22) International Filing Date:
11 March 2020 (11.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/817,152 12 March 2019 (12.03.2019) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK** [CA/CA]; 190 Elizabeth Street, R. Fraser Elliot Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors: **BROKX, Richard**; c/o University Health Network, 190 Elizabeth Street, R. Fraser Elliot Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA). **MASON, Jacqueline M.**; c/o University Health Network, 190 Elizabeth Street, R. Fraser Elliot Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA). **BRAY, Mark R.**; c/o University Health Network, 190 Elizabeth Street, R. Fraser Elliot Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(74) Agent: **BOWN, Christopher** et al.; GOWLING WLG (CANADA) LLP, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TSG-6 ANTIBODIES AND USES THEREFOR

Figure 1

Clone ID	IC_{50} – inhibition of HA binding (nM)
2B4	>2000
2G11	>667
3E1	>667
5A5	>667
4E4	>667
1A9	32
1D12	>667
1D7	47
3C6	10
3E4	290
4F1	>667
5B4	>667
5D9	~1400

(57) Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

WO 2020/181376 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*